FDA approval history Drug class: atypical antipsychotics Breastfeeding En español Professional resources Rexulti prescribing information Brexpiprazole (AHFS Monograph) Related treatment guides Agitation Associated with Dementia Due to Alzheimer’s Disease Major Depressive Disorder Schizophrenia DepressionFurther inf...
FDA approval history Drug class: atypical antipsychotics Breastfeeding En español Patient resources Rexulti drug information Professional resources Rexulti prescribing information Brexpiprazole (AHFS Monograph) Related treatment guides Agitation Associated with Dementia Due to Alzheimer’s Disease Major Depressiv...
Approval: 2015 WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Elderly patients with dementia-related psychosis treated with anti......
(5.3) Initial U.S. Approval: 2015 • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring. (5.4) WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS • Tardive Dyskinesia: Discontinue if clinically appropriate. (5.5) WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL ...
Otsuka and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI® (brexpiprazole) for the treatment of schizophrenia in pediatric patients 13 to 17 years of age. The FDA prev
Agitation symptoms negatively impact functioning, disease progression, quality of life and care for about half of Alzheimer’s dementia patients – and are a consistent predictor of nursing home admission.5,6 REXULTI®is the first ...
Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI ® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17. PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS W...
There may be other side effects of Rexulti that are not listed here. Contact your healthcare provider if you think you are having a side effect of a medicine. In the U.S., you can report side effects to the FDA atwww.fda.gov/medwatchor by calling 800-FDA-1088. In Canada, you can...
Rexulti is not approved to treat dementia-related psychosis. Other Medicines and Supplements. Rexulti may interact with other medicines and supplements. Before using Rexulti, tell your healthcare provider about any prescription or over-the-counter (OTC) medicines, vitamins/minerals, herbal products, ...